九洲药业公告称，2025年12月12日，控股股东中贝集团解除质押给多家银行共2850万股公司无限售流通 股。中贝集团持有公司股份2.84亿股，占总股本31.88%，本次解质后累计质押2300万股，占其持股的 8.11%，占总股本2.59%。中贝集团及其一致行动人合计持股3.94亿股，占比44.35%，累计质押股份占其 持股的5.83%，占总股本2.59%，本次解质股份暂无后续质押计划。 ...

Core Points - The announcement details the pledge and release of shares by the major shareholder, Beijing Jiangheyuan Holdings Co., Ltd. (referred to as "Jiangheyuan"), which holds approximately 31,564.52 million shares, accounting for 27.86% of the company's total share capital [1][2] - Jiangheyuan has pledged a total of 10,850 million shares, representing 34.37% of its holdings and 9.58% of the company's total share capital [1][2] - The purpose of the recent share pledge financing is to supplement working capital, with no involvement in major asset restructuring or performance compensation [1] Share Pledge Details - Jiangheyuan has engaged in share pledge financing with Huaneng Guicheng Trust Co., Ltd., pledging 3,350 million shares, which is 10.61% of its holdings [1] - The release of 5,550 million shares occurred, which is 17.58% of Jiangheyuan's holdings and 4.90% of the company's total share capital [1] - After the release, Jiangheyuan has 10,850 million shares still pledged, which is 34.37% of its holdings and 9.58% of the company's total share capital [1] Financial Position - Jiangheyuan and its concerted actor, Liu Zaiwang, have a total of 60,495.31 million shares pledged, which is 53.39% of their total holdings [2] - The repayment sources for Jiangheyuan include operational cash flow, investment income, and company dividends [2]